Dlac200 ml

Dlac 200 ml is an osmotic (hyperosmolar) laxative prescribed for the management of the following conditions:

Chronic Constipation

Dlac 200 ml is indicated for the treatment of chronic constipation and for maintaining regular, comfortable bowel movements. In every case of chronic constipation, first-line management should include a fiber-rich diet (vegetables, salads, and fruits), a generous intake of fluids, and adequate physical exercise. Dlac 200 ml is recommended only when these lifestyle measures alone prove insufficient to relieve symptoms.

Intestinal Flora Disturbances

Dlac 200 ml supports the restoration of healthy gut flora and is used in conditions where the intestinal microbiome is disrupted, including:

• Damage to intestinal flora, such as that following long-term antibiotic therapy
• Gall bladder disorders
• Intestinal diseases including colitis, diverticulosis, and megacolon

Elevated Blood Ammonia (Hepatic Conditions)

Dlac 200 ml is indicated for the reduction of raised blood ammonia levels (hyperammonaemia) associated with liver disease, including hepatopathy and portal-systemic (hepatic) encephalopathy. By lowering ammonia absorption from the gut, it helps improve the mental state of patients with hepatic encephalopathy.

Dlac 200 ml is a hyperosmolar laxative widely used as an effective and well-tolerated treatment for constipation. It is a synthetic, non-absorbable disaccharide that works by drawing water into the bowel through osmosis. This increased fluid content causes distention of the intestine, softens the stool, and accelerates bowel movement. Because it is not absorbed into the bloodstream in significant amounts, Dlac 200 ml acts locally within the colon, making it suitable for long-term use in adults, children, infants, and elderly patients when prescribed appropriately.

Osmotic purgatives (osmotic laxatives).

Dlac 200 ml is a synthetic disaccharide composed of galactose and fructose. It passes through the small intestine unchanged, as the body lacks the enzymes required to break it down. Upon reaching the colon, Dlac 200 ml is metabolized by saccharolytic (sugar-fermenting) bacteria into low-molecular-weight organic acids, primarily lactic acid, along with small amounts of acetic and formic acid.

These organic acids lower the pH of the colonic contents and promote the retention of water through an osmotic effect. The resulting increase in stool water content and volume stimulates peristaltic activity, easing the passage of stool. In hepatic encephalopathy, the acidification of the colon converts absorbable ammonia (NH₃) into non-absorbable ammonium ions (NH₄⁺), which are then excreted, thereby reducing blood ammonia concentration. Since Dlac 200 ml is only minimally absorbed, its systemic pharmacokinetics are not relevant to its principal therapeutic action.

Dlac 200 ml has no clinically significant drug interactions when used as directed. However, a few considerations should be noted:

• Excessive or prolonged misuse of Dlac 200 ml may cause potassium loss, which can intensify the effects of cardiac glycosides (such as digoxin).
• Concurrent use with other laxatives is generally not recommended during the treatment of hepatic encephalopathy, as loose stools may falsely suggest that an adequate Dlac 200 ml dose has been reached.
• Because Dlac 200 ml acidifies the colon, medications designed to release in a pH-dependent manner in the colon may theoretically be affected.

Dlac 200 ml is generally well tolerated. Mild side effects may occur, particularly at the start of treatment, and usually resolve as therapy continues or when the dose is adjusted. Commonly reported effects include:

• Flatulence (gas), which often subsides after the first few days of treatment
• Abdominal cramps and discomfort at the beginning of therapy, typically relieved by reducing the dose
• Nausea and vomiting
• Diarrhoea, usually associated with higher-than-recommended doses

Prolonged use or misuse at excessive doses may lead to loss of electrolytes, primarily potassium. If severe or persistent diarrhoea, dehydration, or electrolyte imbalance occurs, the dose should be reduced or treatment reviewed by a physician.

The US FDA Pregnancy Category of Dlac 200 ml is B. Available studies indicate that Dlac 200 ml has no known adverse effects on pregnancy, as it is minimally absorbed and acts locally within the gut. It is generally considered one of the safer laxative options during pregnancy and breastfeeding. Nevertheless, decisions regarding its use during pregnancy and lactation should be made by a registered physician after weighing the benefits and risks.

Certain precautions should be observed when using Dlac 200 ml:

• Administer with care to patients who are intolerant to Dlac 200 ml or have difficulty digesting sugars.
• The higher doses used in the treatment of hepatic (pre)coma contain a considerable amount of sugar, which should be taken into account in patients with diabetes mellitus.
• Prolonged use at high doses may cause diarrhoea and electrolyte disturbances; monitoring may be required, especially in the elderly and debilitated patients.
• If no therapeutic effect is observed after several days, or if constipation persists, consult a physician for reassessment.
• Patients with rare hereditary conditions such as galactose or fructose intolerance should avoid Dlac 200 ml.

There have been no reports of serious accidental overdose with Dlac 200 ml. In the event of acute overdose, the main symptoms are expected to be diarrhoea and abdominal cramps. Excessive dosing may also lead to fluid loss, dehydration, and electrolyte imbalance—particularly loss of potassium. Management is generally supportive: discontinue or reduce the dose, and correct any fluid or electrolyte disturbances. Seek medical attention if symptoms are severe or persistent.

Keep Dlac 200 ml in a dry place, protected from light and heat. Do not freeze. Keep the bottle tightly closed after use. Keep out of the reach of children. Do not use after the expiry date printed on the container.

Pediatric Use: Dlac 200 ml may be used in infants, toddlers, and children under close medical supervision, with the dose carefully adjusted for age and body weight. Special care is needed in infants to avoid dehydration and electrolyte imbalance.

Geriatric Use: Elderly patients can use Dlac 200 ml safely, but they may be more sensitive to fluid and electrolyte loss during prolonged therapy; monitoring is advisable.

Patients with Diabetes: The sugar content of Dlac 200 ml is usually negligible at normal laxative doses. However, the high doses used for hepatic encephalopathy require caution and possible dose adjustment in diabetic patients.

Hepatic and Renal Impairment: Dlac 200 ml is frequently used in liver disease and is not significantly absorbed, so dose adjustment for renal impairment is generally not required. Use should always be guided by a physician.